JP2001504813A - 代用血小板、及びそれらの製造に適した抱合法 - Google Patents

代用血小板、及びそれらの製造に適した抱合法

Info

Publication number
JP2001504813A
JP2001504813A JP51910098A JP51910098A JP2001504813A JP 2001504813 A JP2001504813 A JP 2001504813A JP 51910098 A JP51910098 A JP 51910098A JP 51910098 A JP51910098 A JP 51910098A JP 2001504813 A JP2001504813 A JP 2001504813A
Authority
JP
Japan
Prior art keywords
fibrinogen
product
albumin
protein
spacer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP51910098A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001504813A5 (https=
Inventor
デイビッド、ヒース
サラ、マーガレット、ミドルトン
ロイ、ハリス
ニコラ、ジャーン、チャーチ
Original Assignee
クウォドラント、ヘルスケアー、（ユーケー）、リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26310263&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2001504813(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9621886.2A external-priority patent/GB9621886D0/en
Priority claimed from GBGB9702652.0A external-priority patent/GB9702652D0/en
Application filed by クウォドラント、ヘルスケアー、（ユーケー）、リミテッド filed Critical クウォドラント、ヘルスケアー、（ユーケー）、リミテッド
Publication of JP2001504813A publication Critical patent/JP2001504813A/ja
Publication of JP2001504813A5 publication Critical patent/JP2001504813A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
JP51910098A 1996-10-21 1997-10-17 代用血小板、及びそれらの製造に適した抱合法 Pending JP2001504813A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9621886.2 1996-10-21
GBGB9621886.2A GB9621886D0 (en) 1996-10-21 1996-10-21 Microparticles and their therapeutic use
GBGB9702652.0A GB9702652D0 (en) 1997-02-10 1997-02-10 Conjugates and their preparation
GB9702652.0 1997-02-10
PCT/GB1997/002877 WO1998017319A2 (en) 1996-10-21 1997-10-17 Platelet substitutes and conjugation methods suitable for their preparation

Publications (2)

Publication Number Publication Date
JP2001504813A true JP2001504813A (ja) 2001-04-10
JP2001504813A5 JP2001504813A5 (https=) 2005-06-16

Family

ID=26310263

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51910098A Pending JP2001504813A (ja) 1996-10-21 1997-10-17 代用血小板、及びそれらの製造に適した抱合法

Country Status (10)

Country Link
US (1) US5977313A (https=)
EP (1) EP1028752B1 (https=)
JP (1) JP2001504813A (https=)
AR (1) AR008680A1 (https=)
AT (1) ATE284714T1 (https=)
AU (1) AU718956B2 (https=)
CA (1) CA2269335C (https=)
DE (1) DE69731985T2 (https=)
ES (1) ES2232862T3 (https=)
WO (1) WO1998017319A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005504745A (ja) * 2001-07-20 2005-02-17 シエーリング　アクチエンゲゼルシヤフト 大環状金属錯体及び生体分子との結合体の製造のためのその使用
JP2011520913A (ja) * 2008-05-16 2011-07-21 バイエル・ヘルスケア・エルエルシー 標的化凝固因子およびそれを使用する方法

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391343B1 (en) 1991-01-15 2002-05-21 Hemosphere, Inc. Fibrinogen-coated particles for therapeutic use
WO1998055105A1 (en) 1997-06-05 1998-12-10 Hemosphere, Inc. Fibrinogen-coated microspheres
GB9724143D0 (en) * 1997-11-14 1998-01-14 Andaris Ltd Pharmaceutical conjugate
WO1999042146A1 (en) * 1998-02-20 1999-08-26 Quadrant Healthcare (Uk) Limited Products comprising fibrinogen for use in therapy
GB9825105D0 (en) * 1998-11-16 1999-01-13 Andaris Ltd Pharamaceutical conjugates
GB9827813D0 (en) * 1998-12-17 1999-02-10 Andaris Ltd Pharmaceutical conjugates
DE19926475A1 (de) * 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
US7402392B2 (en) * 2001-10-03 2008-07-22 Vanderbilt University In vivo panning for ligands to radiation-induced molecules
US7906102B2 (en) 2001-10-03 2011-03-15 Vanderbilt University Ligands to radiation-induced molecules
US7306925B2 (en) 2001-11-09 2007-12-11 Vanderbilt University Phage antibodies to radiation-inducible neoantigens
GB0323378D0 (en) * 2003-10-07 2003-11-05 Univ Leicester Therapeutic agent
GB0516091D0 (en) * 2005-08-04 2005-09-14 Haemostatix Ltd Therapeutic agent
US20080015145A1 (en) * 2006-07-11 2008-01-17 Maria Gyongyossy-Issa Mimotope receptors and inhibitors for platelet-platelet and platelet-endothelium interactions
GB0623607D0 (en) 2006-11-27 2007-01-03 Haemostatix Ltd Tissue adhesive
PL2435028T3 (pl) 2009-05-28 2017-09-29 Profibrix Bv Uszczelniacz fibrynowy w postaci suchego proszku
GB201101740D0 (en) * 2011-02-01 2011-03-16 Haemostatix Ltd Therapeutic agents with improved fibrinogen binding
WO2013019730A1 (en) 2011-07-29 2013-02-07 The Washington University Antibodies to tip-1 and grp78
GB201201751D0 (en) 2012-02-01 2012-03-14 Haemostatix Ltd Haemostatic wound dressing
US20130202675A1 (en) 2012-02-03 2013-08-08 Dynasil Biomedical Corporation Systems and methods for the fabrication of tissue patches
GB201204868D0 (en) 2012-03-20 2012-05-02 San Raffaele Centro Fond Peptides
US10449261B2 (en) 2014-07-24 2019-10-22 Washington University Compositions targeting radiation-induced molecules and methods of use thereof
US9540548B1 (en) 2015-08-07 2017-01-10 Xcede Technologies, Inc. Adhesive compositions and related methods
US9833538B2 (en) 2015-08-07 2017-12-05 Xcede Technologies, Inc. Adhesive compositions and related methods
CA2994959A1 (en) 2015-08-07 2017-02-16 Xcede Technologies, Inc. Adhesive compositions and related methods
CN107686508B (zh) * 2016-08-05 2021-02-12 首都医科大学 阿霉素-rgds,其合成,活性和应用
CN107686507B (zh) * 2016-08-05 2021-02-12 首都医科大学 Rgds-阿霉素,其合成,活性和应用
US11352436B2 (en) 2017-02-10 2022-06-07 Washington University Antibodies to TIP1 and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039128A1 (en) * 1995-06-06 1996-12-12 Hemosphere, Inc. Protein particles for therapeutic and diagnostic use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334499D0 (en) * 1983-12-24 1984-02-01 Beecham Group Plc Derivatives
GB8400653D0 (en) * 1984-01-11 1984-02-15 Beecham Group Plc Conjugates
US4661471A (en) * 1984-04-10 1987-04-28 New England Deaconess Hospital Method of inhibiting and inducing human platelet aggregation
US4666884A (en) * 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
US5069936A (en) * 1987-06-25 1991-12-03 Yen Richard C K Manufacturing protein microspheres
AU3149289A (en) * 1988-03-18 1989-09-21 Rockefeller University, The Method and agent for inhibiting the binding of human polymorphonuclear leukocytes to endothelium and compositions therefor
WO1990003401A1 (en) * 1988-09-30 1990-04-05 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having schiff base linkages
DK0494417T3 (da) * 1991-01-10 1996-05-13 Basf Corp Fremgangsmåde til tværbinding af gelatine og til inkorporering af et materiale deri
US5725804A (en) * 1991-01-15 1998-03-10 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
US5616311A (en) * 1991-01-15 1997-04-01 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
EP0495187B1 (en) * 1991-01-15 1997-01-22 Hemosphere, Inc. Protein nanomatrixes and method of production
WO1992013495A1 (en) * 1991-02-07 1992-08-20 Fibratek, Inc. Fibrinogen based adhesive
WO1992013547A1 (en) * 1991-02-07 1992-08-20 Alexander Mellon Eaton Drug delivery composition and method of using the same
GB9107628D0 (en) * 1991-04-10 1991-05-29 Moonbrook Limited Preparation of diagnostic agents
EP0673384A4 (en) * 1992-12-10 1996-10-09 Univ Minnesota POLYPEPTIDES USEFUL IN TREATING INFLAMMABLE DISEASES.
GB9423419D0 (en) * 1994-11-19 1995-01-11 Andaris Ltd Preparation of hollow microcapsules
PT796090E (pt) * 1994-12-16 2003-07-31 Elan Drug Delivery Ltd Microparticulas reticuladas e sua utilizacao como veiculos terapeuticos
EP0727225A3 (en) * 1995-02-14 1997-01-15 Sonus Pharma Inc Compositions and methods for directed ultrasonic imaging

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039128A1 (en) * 1995-06-06 1996-12-12 Hemosphere, Inc. Protein particles for therapeutic and diagnostic use

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005504745A (ja) * 2001-07-20 2005-02-17 シエーリング　アクチエンゲゼルシヤフト 大環状金属錯体及び生体分子との結合体の製造のためのその使用
JP2011520913A (ja) * 2008-05-16 2011-07-21 バイエル・ヘルスケア・エルエルシー 標的化凝固因子およびそれを使用する方法
US9422362B2 (en) 2008-05-16 2016-08-23 Bayer Healthcare Llc Targeted coagulation factors and method of using the same
JP2017025065A (ja) * 2008-05-16 2017-02-02 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 標的化凝固因子およびそれを使用する方法
US10035840B2 (en) 2008-05-16 2018-07-31 Bayer Healthcare Llc Targeted coagulation factors and method of using the same

Also Published As

Publication number Publication date
AR008680A1 (es) 2000-02-09
ES2232862T3 (es) 2005-06-01
WO1998017319A2 (en) 1998-04-30
AU718956B2 (en) 2000-05-04
ATE284714T1 (de) 2005-01-15
DE69731985T2 (de) 2005-12-29
DE69731985D1 (de) 2005-01-20
EP1028752B1 (en) 2004-12-15
CA2269335A1 (en) 1998-04-30
AU4713597A (en) 1998-05-15
WO1998017319A3 (en) 1998-06-11
CA2269335C (en) 2010-05-25
US5977313A (en) 1999-11-02
EP1028752A2 (en) 2000-08-23

Similar Documents

Publication Publication Date Title
JP2001504813A (ja) 代用血小板、及びそれらの製造に適した抱合法
JP4350165B2 (ja) 架橋した微細粒子、及びそれら粒子の治療薬用ビヒクルとしての使用
US5955108A (en) Cross-linked microparticles and their use as therapeutic vehicles
FI117124B (fi) Biohajoavista kopolymeereistä koostuvia mikrohiukkasvalmisteita
JPH07508004A (ja) プロテイノイド担体並びにその製造方法および使用方法
RU2503464C2 (ru) Биогель
Cheng et al. Facile assembly of cost-effective and locally applicable or injectable nanohemostats for hemorrhage control
JP2939341B2 (ja) 赤血球代用剤
EP1919508B1 (en) Artificial platelets
JP2001523648A (ja) ２種の活性剤を含むコンジュゲート
JPH09504790A (ja) 化学的触媒作用および細胞受容体活性化のための生化学的活性物質
CN112274654B (zh) 靶向载药纳米胶束、其制备方法和应用
CN104758945B (zh) 一种pH响应的溶栓药物靶向纳米凝胶及其合成方法和用途
MXPA99003677A (en) Platelet substitutes and conjugation methods suitable for their preparation
CN100360554C (zh) 肽缀合物
CN1240364A (zh) 血小板替代物和适于其制备的缀合方法
WO2000035487A1 (en) Pharmaceutical conjugates comprising two active agents
US20040235719A1 (en) Soluble protein-polymer systems for drug delivery
MXPA97004503A (en) Steril powder of interlocked materials and its
WO2000029028A1 (en) Pharmaceutical conjugates of glycoproteins and insoluble carriers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041014

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041014

A72 Notification of change in name of applicant

Free format text: JAPANESE INTERMEDIATE CODE: A721

Effective date: 20061129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080527

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080827

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080922

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091009

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20091210

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100527

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20130321